- Home
- BGMS vs PULM Comparison
BGMS vs PULM Comparison
Compare BGMS & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGMS | PULM |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | Malaysia | United States |
| Employees | 19 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.2M |
| IPO Year | 2000 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BGMS | PULM |
|---|---|---|
| Price | $0.94 | $1.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 171.6K | 41.9K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $80,482.35 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $0.57 | $1.16 |
| 52 Week High | $6.70 | $5.50 |
Technical Indicators
Market Signals| Indicator | BGMS | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 58.66 |
| Support Level | $0.82 | $1.61 |
| Resistance Level | $0.93 | $1.66 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 46.20 | 67.27 |
Price Performance
Historical ComparisonAbout BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is engaged in the supply and trading of protective and fire safety equipment. The company distributes products such as fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and safety apparel. It also provides fire safety systems, including sprinkler systems, fire alarm systems, valves, and CO2 systems. The company operates across commercial, industrial, healthcare, and residential sectors, with a focus on distribution and compliance with applicable safety standards.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).